{"nctId":"NCT03945019","briefTitle":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)","startDateStruct":{"date":"2019-10-28","type":"ACTUAL"},"conditions":["Crohn's Disease"],"count":396,"armGroups":[{"label":"CT-P13 SC","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P13 SC (Infliximab)"]},{"label":"Placebo SC","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo SC"]}],"interventions":[{"name":"CT-P13 SC (Infliximab)","otherNames":[]},{"name":"Placebo SC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is male or female aged 18 to 75 years, inclusive.\n* Patient who has moderately to severely active CD with a score on the CDAI of 220 to 450 points\n\nExclusion Criteria:\n\n* Patient who has previously received either a TNFα inhibitor or biological agent within 5 half-lives\n* Patient who has previously demonstrated inadequate response or intolerance to TNFα inhibitors for the treatment of CD.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54","description":"Clinical remission was defined as an absolute Crohn's Disease Activity Index (CDAI) score of \\<150 points.\n\nThe total CDAI scores range from 0 to over 600 with higher scores indicating increased severity of disease. The index is the sum of 8 components; number of liquid or very soft stools, abdominal pain, general well-being, CD complications, taking antidiarrheal drugs, abdominal mass, hematocrit, and weight.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Achieving Endoscopic Response (Based on Central SES-CD) at Week 54","description":"Endoscopic response was defined as a 50% decrease in Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD) score from the baseline value.\n\nThe SES-CD assesses the size of mucosal ulcers, ulcerated surface, endoscopic extension and the presence of stenosis. Each item is scored from 0-3, with total score from 0-60. Higher score indicates more severe endoscopic activity.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-responder.\n\nStatistical testing for this outcome based on the colonoscopy (SES-CD) was conducted using the colonoscopy reading results of central level.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving CDAI-100 Response at Week 54","description":"Crohn's Disease Activity Index (CDAI)-100 response was defined as a decrease in CDAI score of 100 points or more from the baseline value.\n\nThe total CDAI scores range from 0 to over 600 with higher scores indicating increased severity of disease. The index is the sum of 8 components; number of liquid or very soft stools, abdominal pain, general well-being, CD complications, taking antidiarrheal drugs, abdominal mass, hematocrit, and weight.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-responder.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Clinical Remission (Based on AP and SF) at Week 54","description":"Clinical remission was defined as an average worst daily Abdominal Pain (AP) score of ≤1 (using 4-point scale) and an average daily loose/watery Stool Frequency (SF) score of ≤3 (of Type 6 or Type 7 on Bristol Stool Form Scale (BSFS)) with no worsening in either average score compared with the baseline value.\n\nAP score is patient recorded score on a scale 0 to 3 (none, mild, moderate, or severe) and higher score indicates severe abdominal pain. SF score is patient recorded number of loose/watery stool defined as BSFS type 6 or 7 per day. BSFS is an ordinal scale of stool types ranging from the hardest (Type 1) to the softest (Type 7).\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Endoscopic Remission (Based on Central SES-CD) at Week 54","description":"Endoscopic remission was defined as an absolute Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD) score of ≤4 and at least 2-point reduction from the baseline value with no segment sub-score of \\>1.\n\nThe SES-CD assesses the size of mucosal ulcers, ulcerated surface, endoscopic extension and the presence of stenosis. Each item is scored from 0-3, with total score from 0-60. Higher score indicates more severe endoscopic activity.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":396},"commonTop":["COVID-19","Headache","Crohn's disease","Anaemia","Injection site reaction"]}}}